H361：Suspected of damaging fertility or the unborn child
Precautionary statements
P201：Obtain special instructions before use.
P202：Do not handle until all safety precautions have been read and understood.
P281：Use personal protective equipment as required.
P308+P313：IF exposed or concerned: Get medical advice/attention.
P405：Store locked up.
P501：Dispose of contents/container to..…
Description
Nazasetron (azasetron) hydrochloride is the fourth in the class of highly potent 5-
HT3 receptor antagonists to reach the market for prophylaxis of severe nausea and
vomiting induced by cytotoxic chemotherapy and by total body X-radiation. In a
study with 146 cancer patients suffering from emesis induced by cisplatin,
nazasetron was reported to be markedly effective in 72% of subjects. Nazasetron is
devoid of dopamine D2 receptor blocking activity and therefore is free of the
extrapyrimidal side effects associated with other commonly used antiemetics such
as metoclopramide and domperidone. Nazasetron has been reported to be
potentially useful for the treatment of gastrointestinal motility dysfunction, such as
gastric stasis, vomiting and irritable bowel syndrome.
